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Glucocorticoid-Induced Leucine Zipper (GILZ) is a glucocorticoid-inducible gene that mediates gluco-
corticoid anti-inﬂammatory effects. GILZ and the isoform L-GILZ are expressed in a variety of cell types,
especially of hematopoietic origin, including macrophages, lymphocytes and epithelial cells, and strongly
upregulated upon glucocorticoid treatment.
A quantitative analysis of GILZ expression in mouse tissues is technically difﬁcult to perform because
of the presence of a pseudogene and the high homology of GILZ gene with other genes of TSC22 family.
We here propose speciﬁc primer pairs to be used in Real Time PCR to avoid unwanted ampliﬁcation of
GILZ pseudogene and TSC-22 family member d1iso3. These primer pairs were used to determine GILZ
and L-GILZ expression, in either untreated or in vivo and in vitro dexamethasone-treated tissues. Results
indicate that GILZ and L-GILZ are upregulated by glucocorticoids, being GILZ more sensitive to gluco-
corticoid induction than L-GILZ, but they are differently expressed in all examined tissues, conﬁrming a
different role in speciﬁc cells. An inappropriate primer pair ampliﬁed also GILZ pseudogene and
TSC22d1iso3, thus producing misleading results. This quantitative evaluation may be used to better
characterize the role of GILZ and L-GILZ in mice and may be translated to humans.
& 2015 Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Glucocorticoid-Induced Leucine Zipper (GILZ) is a
glucocorticoid-inducible gene belonging to the TSC22 family,
whose members share TSC box and leucine zipper domains. GILZ
is one of the earliest and rapidly induced gene by glucocorticoids
(GCs), mainly in lymphoid cells, which regulates activation and
apoptosis. Evidence is accumulating that GILZ is an important
mediator of GC anti-inﬂammatory effects in cell lineages and in
inﬂammatory mouse models, through inhibition of the expression
of pro-inﬂammatory genes [1,10,13,16,3,5]. This effect depends on
the ability of GILZ to homo- and hetero-dimerize, thereby acting as
a regulator of gene transcription.
L-GILZ is an isoform of GILZ capable to bind Ras. It is particu-
larly expressed in testis, where its absence causes failure of sper-
matogenesis [23,26,8]. In addition, L-GILZ has been found to
mediate the anti-myogenic effect of GCs [7] and, interestingly, can
bind p53, thus leading to tumor growth suppression [2].s article under the CC BY-NC-ND li
chetti).Although GILZ and L-GILZ have been studied in diverse cell
types, especially in the immune system, a systematic analysis of
their tissue distribution has never been done. Furthermore, the
high homology of GILZ with TSC22d1 and the existence of a GILZ
pseudogene may lead to false results of GILZ expression.
We here show the data that prompted us to ﬁnd a speciﬁc
strategy to amplify undoubtedly GILZ through quantitative Real
Time PCR. Finally, by using this method, we performed a deep
analysis of GILZ and L-GILZ expression in immune and non-
immune tissues and in the same tissues after exposure to gluco-
corticoids (GC), both in vitro and in vivo.2. Materials and methods
2.1. In vivo and in vitro dexamethasone treatment
Six–eight weeks old C57Bl/6 mice were treated with dex-
amethasone (DEX) 10 mg/kg by intraperitoneal administration, 3 h
before sacriﬁce and removing organs. In vitro experiments were
performed by reducing organs to single cell suspension through
cell strainer separation and treating cells (2106/ml) by either
DEX 106 and 107 M for 3 h.cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
L. Cari et al. / Results in Immunology 5 (2015) 37–42382.2. Reverse transcriptase PCR
The RNA of tissues or single cells was isolated using the Trizol
reagent (Ambion, Life Technologies), and conversion of total RNA
to cDNA was performed with the QuantiTect Reverse Transcription
Kit (Qiagen) according to the manufacturer’s instructions. PCR was
performed with 20 ng of cDNA, and all primers are listed in sup-
plementary Table 1. Taq polymerase was purchased from Life
Technologies. For primer couples A-B and C-D reactions were
incubated in a 96-well Eppendorf Mastercycler ep gradient S at
95 °C for 15 s, 60 °C for 20 s and 72 °C for 30 s, 34 cycles. For pri-
mer couple E-F reactions were incubated in a 96-well Eppendorf
Mastercycler ep gradient S at at 95 °C for 30 s, 58 °C for 20 s and
72 °C for 30 s, 36 cycles. For primer couple W-Z reactions were
incubated in a 96-well Eppendorf Mastercycler ep gradient S at
95 °C for 30 s, 57 °C for 20 s and 72 °C for 30 s, 36 cycles.
2.3. Real Time PCR
Real Time PCR reactions were performed using the ABI 7300
Real Time Cycler (Applied Biosystems), and ampliﬁcation was
achieved using the Sybr select master mix (Applied Biosystems)
with primers listed in supplementary Table 1. Time and tempera-
ture conditions are the same as described above. GAPDH was used
as housekeeping gene and its expression was evaluated by Taqman
assay using standard conditions (4352339E, Life Technologies). All
experiments were carried out in triplicate, and the ΔΔCt method
was used to determine expression of GILZ and L-GILZ.3. Results
3.1. Non-speciﬁc PCR ampliﬁcation with some primers for GILZ
When we tried to amplify GILZ by reverse transcriptase PCR
(RT-PCR), we found that several couples of primers located along
GILZ mRNA (for instance, Forward primer in exon 3-W- and
Reverse primer in exon 6-Z) ampliﬁed a product even in GILZ
knock-out (KO) cells, demonstrating that they amplify other
sequences homologous to GILZ (Fig. 1a and b).Fig. 1. PCR strategy to amplify GILZ and L-GILZ: (a) structure of GILZ gene, GILZ mRNA an
(d), A and B represent the primers used in the RT-PCR shown in (c), whereas C and D a
(c) RT-PCR performed with A and B primers. (d) Restriction enzyme digestion performed
derived cDNA. The expected lengths of digested fragments are indicated for each ampliﬁe
to amplify L-GILZ. (g) RT-PCR to amplify L-GILZ in testis.In an attempt to ﬁnd genes sharing high homology with mur-
ine GILZ, in chromosome 1 we found a pseudogene (NC_000067.6,
66062746-66064858, NCBI, February 2015) that shows 95% overall
homology to GILZ. The major portion of the small difference
between GILZ and the pseudogene is due to non-contiguous point
mutations (see, for example, supplementary Fig. 1). Moreover, the
pseudogene shows a 191 bp sequence in a region located in exon
6, which is missing in GILZ (dotted in Fig. 1a). To demonstrate that
GILZ pseudogene can be ampliﬁed, we used primers A and B
located in exon 6 (Fig. 1a), which can theoretically amplify both
GILZ (177 bp) and its pseudogene (361 bp). Fig. 1c shows that GILZ
pseudogene can be ampliﬁed and derived from genomic DNA
contamination of cDNA samples, as demonstrated by the fact that
ampliﬁcation is observed in RNA samples in which RT has not been
performed (not shown).
TSC22 family member TSC22d1iso3 (NM_001177751.2) is
another gene that shows a high homology with GILZ. In particular,
the homology is very high between the exon 5 of GILZ and the
exon 2 of TSC22d1iso3, and the exon 6 of GILZ and the exon 3 of
Tsc22d1iso3 (supplementary Fig. 1). There is even some homology
between the exon 3 of GILZ and the exon 1 of TSC22d1iso3. Rea-
sonably, some couples of primers annealing on regions of high
similarity between GILZ and TSC22d1iso3 can amplify GILZ toge-
ther with TSC22d1iso3. To test whether this was the case, we
designed a strategy of digestion of PCR products with 2 restriction
enzymes (supplementary Fig. 1 and Table 2). The digestion relea-
ses 3 different fragments, which are TSC22d1iso3, GILZ pseudo-
gene and GILZ. Digestion of the WT PCR products shown in Fig. 1d
clearly demonstrates that this primer pair ampliﬁes not only GILZ,
but also TSC22D1 and the pseudogene (Fig. 1d). This result sug-
gests that quantiﬁcation of GILZ is not accurate, if inappropriate
primers are used, especially when GILZ is expressed at low levels
or not at all. As a consequence, quantitative analysis by Real Time
PCR could be biased.
3.2. Speciﬁc PCR ampliﬁcation of GILZ
In order to circumvent the above problems, we identiﬁed a
speciﬁc region in exon 6 (hatched in Fig. 1a), spanning 7 bp, which
is unique in GILZ and missing in the pseudogene (supplementaryd GILZ pseudogene. W and Z represent the primers used in RT-PCR shown in (b) and
re the primers used in (e). (b) RT-PCR performed with inappropriate primers W–Z.
in the WT PCR product shown in (b). (e) PCR to amplify GILZ. All PCRs used thymus-
d gene: (f) gene structure of L-GILZ compared with GILZ. E and F are speciﬁc primers
Fig. 2. Real Time PCR quantiﬁcation in fresh mouse tissues: (a) and (b) GILZ and
L-GILZ expression was normalized using the housekeeping gene GAPDH. All values
were calculated with respect of thymus, set equal to 1 and expressed in a base 2 log
scale. (c) Comparison of GILZ and L-GILZ in the same tissues as in (a) and (b) in
which values were considered relatively to the housekeeping gene expression,
setting arbitrarily a basal level (X-axis). Results are mean of triplicates7SD of two
experiments, and shown on a base 2 log scale.
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overlapping this region. The same primer presents four mis-
matches with TSC22d1iso3, two of them towards the 3ʹ end of the
primer (-2 and -5, see supplementary Fig. 2). Forward primer
(C) in exon 3 has a perfect match with both GILZ and GILZ pseu-
dogene, and 11 mismatches with TSC22d1iso3, three of them
towards the 3ʹ end of the primer (-2, -3 and -5, see supplementary
Fig. 2). Therefore, it is reasonable to hypothesize that the primer
pair C–D uniquely ampliﬁes GILZ, as demonstrated by the absence
of GILZ in KO mice (Fig. 1e). A further proof is the digestion of the
PCR product from WT mice with BspEI restriction enzyme (not
shown), whose site is present in GILZ but not in
TSC22d1iso3 mRNA.
3.3. Speciﬁc ampliﬁcation of L-GILZ
The GILZ pseudogene does not include exon 1 and 2 of L-GILZ
and, to our knowledge, the other genes belonging to TSC22 do not
present similar isoforms. Therefore, it can be hypothesized that L-
GILZ speciﬁc primers amplify uniquely L-GILZ. Indeed, when we
tested forward primer E and reverse primer F (annealing to exon
2 and exon 6, respectively), ampliﬁcation of L-GILZ was obtained in
WT and none in KO mice (Fig. 1f and g).
3.4. GILZ and L-GILZ tissue distribution and induction by GCs
Once designed the appropriate PCR strategy through the use of
speciﬁc primers (C and D for GILZ, E and F for L-GILZ), a quanti-
tative analysis of GILZ and L-GILZ expression in tissues were per-
formed by Real Time PCR. Fig. 2a and b show GILZ and L-GILZ
expression in a variety of fresh mouse tissues. Fig. 2c summarizes
and compares the expression of both transcripts: GILZ and L-GILZ
are differently expressed in almost all tissues.
Because GILZ is a GC-induced gene, we treated mice with the
synthetic glucocorticoid dexamethasone (DEX) for 3 h, and
recovered tissues from diverse organs. Data in Fig. 3 clearly show
how both GILZ (Fig. 3a) and L-GILZ (Fig. 3b) are upregulated after
GC exposure in almost all tissues. GILZ is more sensitive to GC
induction than L-GILZ, reaching high levels of expression espe-
cially in thymus and in lung.
Lymphoid tissues from untreated mice were further char-
acterized in vitro by 3 h DEX treatment. Two doses of DEX were
used and results shown in Fig. 4 demonstrate that there is always
upregulation of GILZ and L-GILZ after DEX exposure. L-GILZ and
GILZ upregulation is dose-dependent only in thymus and bone
marrow, while is dose-independent in spleen and lymph nodes,
suggesting that a low DEX dose is enough to induce both genes.
3.5. Reliable results with the use of speciﬁc primers
To test whether the use of inappropriate primer couples would
produce biased results in a Real Time PCR assay, we tested the
expression of GILZ and its induction by DEX in some tissues, using
the couple of primer W–Z. Results shown in supplementary Fig. 3
demonstrate that the expression of GILZ investigated by using
inappropriate primers W and Z is completely different from the
one obtained with the speciﬁc primers C and D (left panel) and
that the effect of DEX is underestimated when GILZ expression is
evaluated by inappropriate primers (right panel). This is a con-
sequence of overestimation of GILZ expression in untreated
specimens.
In conclusion, in our opinion the use of C–D primer couple
allows a correct quantiﬁcation of GILZ and the use of E–F primer
couple allows a correct quantiﬁcation of L-GILZ.4. Discussion
The evaluation of gene expression is currently performed
mostly by Real Time PCR. Gene expression is correctly evaluated if
only one gene product is ampliﬁed, by using speciﬁc primers.
Moreover, the ampliﬁcation of contaminating DNA can be simply
avoided by using a forward and a reverse primer annealing in
separate exons. Evaluation of GILZ expression is complicated by
two problems: the presence of a GILZ pseudogene and the high
homology of GILZ with TSC22d1iso3. GILZ pseudogene comprises
all GILZ exons, without any introns. Therefore, GILZ pseudogene
can be ampliﬁed even when using primer annealing on separate
exons, in the presence of contaminating cellular DNA, which is
usually present even in technically good RNA samples. Our data
show that GILZ pseudogene was ampliﬁed even in the presence of
Fig. 3. Modulation of GILZ and L-GILZ investigated by Real Time PCR in fresh mouse
tissues 3 h after in vivo DEX treatment (10 mg/kg). The fold values in each group
were calculated versus the same tissues from untreated mice, set equal to 1, on a
base 2 log scale. Results are mean of triplicates7SD of two experiments.
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ogy between the exon 5 of GILZ and the exon 2 of TSC22d1iso3,
and the exon 6 of GILZ and the exon 3 of TSC22d1iso3 is very high
(supplementary Fig. 1). Therefore, the possibility that a reverse
primer designed on exons 5 and 6 of GILZ anneals also on
Tsc22d1iso3 sequence is quite high. Some homology is also pre-
sent between the exon 3 of GILZ and the exon 1 of TSC22d1iso3
and it is possible that a forward primer designed on exon 3 of GILZ
has some identity with TSC22d1iso3 gene. If this similarity is quite
good in the 3ʹ end of the primer, the possibility that it anneals and
generates a PCR product is good. We show that W–Z primer pair
(Fig. 1a and supplementary Table 1) generated a PCR product
including TSC22d1iso3 isoform, not only in KO tissues but also in
WT cells, despite the presence of GILZ and the pseudogene as
competing templates. The PCR products deriving from GILZ
pseudogene and Tsc22d1iso3 isoform have a very similar length as
GILZ (supplementary Table 1). As a consequence, they cannot be
separated by a gel run. Therefore, the possibility that GILZ
expression is wrongly evaluated using inappropriate primers is
high, as shown in the supplementary Fig. 3.
To avoid the above mentioned problems, we designed primers
C and D having a lower tendency to anneal to GILZ pseudogene
and to TSC22d1iso3 isoform. In particular, the reverse primer D
cannot anneal at the 3ʹ end in the pseudogene sequence, and the 3ʹ
end of both forward and reverse primers are suboptimal for theannealing to TSC22d1iso3 isoform. The lack of any PCR products in
KO cells (Fig. 1g) conﬁrmed that these primers speciﬁcally amplify
GILZ. Importantly, the primer pair C–D has been optimally
designed to work properly at 60 °C, as, for example, in a
Taqman assay.
Anti-inﬂammatory effects of GCs encompass multiple
mechanisms, among which induction of speciﬁc genes in immune
cells represents one of the most important. GILZ is one of the
earliest induced genes and has been widely studied in diverse cell
types, including T cells [11,14,22,24,6], macrophages [18], dendritic
[9] and epithelial cells [19]. However, a systematic screening of
GILZ expression in mouse tissues and its regulation after DEX
treatment has never been done so far.
Our results demonstrate an almost ubiquitous presence of GILZ
in all tissues with low levels in testis, as already known [8], and in
lungs, where a surge in its expression occurs after DEX treatment.
We exactly do not know which is the cell type expressing GILZ in
the lung, but it stands to reason that macrophages could be the
candidate cells. This could be suggested by the observation of a
higher expression of GILZ in spleen than in lymph nodes, main-
tained after in vivo DEX administration, and by previous work
[12,17,18,28]. Such results partially overlap with a very recent
work done in rat tissues [4].
L-GILZ was found to be expressed in all the examined tissues,
and, most importantly, was found to be upregulated by DEX at
different extent. Of note is the more exquisite sensitivity of GILZ
than L-GILZ to DEX induction, as can be observed in Fig. 2c, and
this feature represents a further difference between GILZ and L-
GILZ. Reasonably, this difference is due to the diverse promoter
regions of GILZ and L-GILZ, which are separated by about 54 kb,
thus being differently regulated. Furthermore, GILZ promoter
contains 6 putative Glucocorticoid Responsive Elements (GRE)
while L-GILZ only 4, as assessed by in silico analysis through
Matinspector software (Genomatix). GILZ and L-GILZ even differ in
the intra-cellular localization (L-GILZ is predominantly cyto-
plasmic while GILZ is both in the cytoplasm and in the nucleus)
and function [13,18,1,27,2]. Of note, GILZ and L-GILZ are differently
expressed in untreated tissues as demonstrated here, further
suggesting diverse roles according to the cell type.
The difference in GC sensitivity between GILZ and L-GILZ in vivo
is not reproduced in the in vitro studies from a quantitative point
of view. This is not surprising since different experimental con-
ditions were used. In vivo, distribution of GCs varies according to
the tissues and their metabolism can inﬂuence the response of
cells in tissues and change local GC concentration as well. Fur-
thermore, in vivo GC can modulate activity of immune cells and
their migration, resulting in a different cell type organization in
each lymphoid organ, while untreated organs may be slightly
different. The microenvironment in organs in vivo can inﬂuence
the response to GCs, which does not occur in isolated organs. The
in vivo GC treatment and consequent analysis of GILZ and L-GILZ
induction is very close to what happens under pharmacological
treatment during a disease. However, the common feature is the
raise in expression of GILZ and L-GILZ after GC exposure, which is
maintained in both experimental conditions (in vivo and in vitro).
The application of the strategy proposed here will add new
information about the role played by GILZ in inﬂammation and
cancer and could help ﬁnd a correlation between GILZ/L-GILZ
expression and diseases [15,20,21,25], especially those involving
treatment with GCs. Finally, such a quantitative strategy could be
applied to human cells, since a pseudogene does exist in human
genome (TSC22 domain family member 3 pseudogene LOC
100287033).
Fig. 4. GILZ and L-GILZ expression investigated by Real Time PCR in in vitro DEX-treated lymphoid tissues. Cells from thymus, spleen, bone marrow and lymph nodes were
treated with two doses of DEX, for 3 h. The fold values in each group were calculated versus the same untreated cells, set equal to 1, on a base 2 log scale. Results are mean of
triplicates7SD of two experiments.
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